Gelonghui May 27 丨 Hotview Biology (688068)(688068fabspinscasino.SH) Announcementfabspinscasino, received from the shareholding company Beijing Shunjing Biomedical Technology Co., Ltd.fabspinscasinoAccording to the notification letter from Shunjing Pharmaceutical, the clinical trial application (IND) for the innovative drug SGC001 developed by Shunjing Pharmaceutical was approved by the U.S. Food and Drug Administration (FDA). SGC001 is a monoclonal antibody drug for emergency use jointly developed by the R & D team of Professor Sun Zhiwei of Shunjing Medicine and the team of Professor Du Jie of the Beijing City Institute of Cardiopulmonary and Vascular Diseases of Capital Medical University. It is suitable for emergency treatment of patients with acute myocardial infarction.
